Physician profile
Corey Burr
NPI 1447865357
$3,944.74
in general payments reported to CMS, 2019-2025
15 companies · $1,240 in 2025
The $1,240 reported for 2025 was more than what 93% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $124 · 2021: $455 · 2022: $233 · 2023: $884 · 2024: $1,010 · 2025: $1,240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,134.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $957.94 | 2023-2025 | Infuse, Biotrue, Vyzulta |
| Coopervision INC. | $906.10 | 2020-2025 | Myday Contact Lens |
| Sun Pharmaceutical Industries INC. | $582.91 | 2021-2025 | Cequa |
| Alcon Vision LLC | $487.87 | 2021-2025 | Precision7, Total30, Precision 1 |
| Johnson & Johnson Vision Care, INC. | $344.96 | 2020-2025 | Acuvue |
| Apellis Pharmaceuticals, INC. | $124.05 | 2024 | |
| Tarsus Pharmaceuticals, INC. | $115.25 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $111.58 | 2023-2025 | Tyrvaya, Ryzumvi |
| Abbvie INC. | $95.82 | 2022-2025 | |
| Biotissue Holdings INC. | $55.73 | 2024-2025 | |
| Rxsight INC | $45.45 | 2025 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Mallinckrodt Hospital Products INC. | $36.80 | 2022 | |
| Kala Pharmaceuticals, INC. | $32.64 | 2020 | |
| Harrow Eye, LLC | $28.68 | 2025 | Vevye |
| Optos, INC. | $18.96 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corey Burr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.